These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9394942)

  • 1. Naltrexone in young autistic children: replication study and learning measures.
    Kolmen BK; Feldman HM; Handen BL; Janosky JE
    J Am Acad Child Adolesc Psychiatry; 1997 Nov; 36(11):1570-8. PubMed ID: 9394942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naltrexone in young autistic children: a double-blind, placebo-controlled crossover study.
    Kolmen BK; Feldman HM; Handen BL; Janosky JE
    J Am Acad Child Adolesc Psychiatry; 1995 Feb; 34(2):223-31. PubMed ID: 7896655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Naltrexone and communication skills in young children with autism.
    Feldman HM; Kolmen BK; Gonzaga AM
    J Am Acad Child Adolesc Psychiatry; 1999 May; 38(5):587-93. PubMed ID: 10230191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naltrexone in autistic children: behavioral symptoms and attentional learning.
    Campbell M; Anderson LT; Small AM; Adams P; Gonzalez NM; Ernst M
    J Am Acad Child Adolesc Psychiatry; 1993 Nov; 32(6):1283-91. PubMed ID: 8282676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of chronic naltrexone treatment in young autistic children: a double-blind placebo-controlled crossover study.
    Willemsen-Swinkels SH; Buitelaar JK; van Engeland H
    Biol Psychiatry; 1996 Jun; 39(12):1023-31. PubMed ID: 8780837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Naltrexone in autistic children: a double-blind and placebo-controlled study.
    Campbell M; Anderson LT; Small AM; Locascio JJ; Lynch NS; Choroco MC
    Psychopharmacol Bull; 1990; 26(1):130-5. PubMed ID: 2196621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clonidine treatment of hyperactive and impulsive children with autistic disorder.
    Jaselskis CA; Cook EH; Fletcher KE; Leventhal BL
    J Clin Psychopharmacol; 1992 Oct; 12(5):322-7. PubMed ID: 1479049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study.
    Spencer TJ; Abikoff HB; Connor DF; Biederman J; Pliszka SR; Boellner S; Read SC; Pratt R
    Clin Ther; 2006 Mar; 28(3):402-18. PubMed ID: 16750455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.
    Research Units on Pediatric Psychopharmacology Autism Network
    Arch Gen Psychiatry; 2005 Nov; 62(11):1266-74. PubMed ID: 16275814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
    Biederman J; Melmed RD; Patel A; McBurnett K; Konow J; Lyne A; Scherer N;
    Pediatrics; 2008 Jan; 121(1):e73-84. PubMed ID: 18166547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylphenidate dosing: twice daily versus three times daily.
    Stein MA; Blondis TA; Schnitzler ER; O'Brien T; Fishkin J; Blackwell B; Szumowski E; Roizen NJ
    Pediatrics; 1996 Oct; 98(4 Pt 1):748-56. PubMed ID: 8885956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study.
    Wasserman S; Iyengar R; Chaplin WF; Watner D; Waldoks SE; Anagnostou E; Soorya L; Hollander E
    Int Clin Psychopharmacol; 2006 Nov; 21(6):363-7. PubMed ID: 17012983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
    Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
    Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of naltrexone use in pediatric patients with autistic disorder.
    Elchaar GM; Maisch NM; Augusto LM; Wehring HJ
    Ann Pharmacother; 2006 Jun; 40(6):1086-95. PubMed ID: 16735648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naltrexone plasma levels, clinical response and effect on weight in autistic children.
    Gonzalez NM; Campbell M; Small AM; Shay J; Bluhm LD; Adams PB; Foltz RL
    Psychopharmacol Bull; 1994; 30(2):203-8. PubMed ID: 7831456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder.
    Klassen AF; Miller A; Fine S
    Pediatrics; 2004 Nov; 114(5):e541-7. PubMed ID: 15520087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of methylphenidate among mentally retarded children with attention deficit hyperactivity disorder.
    Handen BL; Breaux AM; Gosling A; Ploof DL; Feldman H
    Pediatrics; 1990 Dec; 86(6):922-30. PubMed ID: 2135682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyproheptadine in the treatment of autistic disorder: a double-blind placebo-controlled trial.
    Akhondzadeh S; Erfani S; Mohammadi MR; Tehrani-Doost M; Amini H; Gudarzi SS; Yasamy MT
    J Clin Pharm Ther; 2004 Apr; 29(2):145-50. PubMed ID: 15068403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study.
    Biederman J; Swanson JM; Wigal SB; Kratochvil CJ; Boellner SW; Earl CQ; Jiang J; Greenhill L
    Pediatrics; 2005 Dec; 116(6):e777-84. PubMed ID: 16322134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.